We are building an active pipeline of products for animal health by applying our proprietary and patented C1 technology to develop vaccines and antibodies for infectious and other diseases.
Vaccine and Antibody Development: C1 platform is ready for full commercialization opportunities in recombinant protein vaccines.
Vaccine Development
The C1 platform is ready for full commercialization opportunities in recombinant protein vaccines.
- Data from animal vaccines produced from C1 proteins have repeatedly demonstrated safety and efficacy in a range of infectious diseases in animal trials with cattle, lambs, and chickens.
- Dyadic has new and expanded collaborations with top animal health companies to develop vaccines for companion and livestock animal diseases.
- Additional recombinant protein projects to support vaccine research and development have been initiated in 2023.
Antibody Development
- Dyadic has an ongoing collaboration with a top animal health company for the development of an antibody for companion animal diseases.
- Additional recombinant protein projects to support vaccine research and development have been initiated in 2023.
Animal Health Pipeline
- Dyadic is currently focusing in the area of zoonotic diseases from animal to human, including Rift-Valley Fever, salmonellosis, zoonotic influenza, West Nile virus, coronavirus, plague, rabies, Lyme disease, and brucellosis.